Literature DB >> 15032626

HDL and inflammation in atherosclerosis.

Lukas E Spieker1, Frank Ruschitzka, Thomas F Lüscher, Georg Noll.   

Abstract

Atherosclerotic vascular disease is among the most frequent causes of death worldwide. Current therapeutic strategies concentrate mainly on lowering of low-density lipoprotein (LDL) cholesterol and an impressive reduction in the risk for cardiovascular morbidity and mortality has been achieved. Inflammatory mechanisms are more and more recognized to play an important role in vascular disease as inflammatory markers correlate with prognosis in acute and chronic coronary artery disease. HDL cholesterol exerts anti-inflammatory effects on the vasculature. Moreover, HDL is an antioxidant, inhibits thrombogenesis, and has pro-fibrinolytic properties. Last but not least, HDL mediates reverse cholesterol transport. These pleiotropic effects make HDL an ideal therapeutic target for novel therapeutic strategies specifically aiming at HDL elevation for the prevention and treatment of atherosclerotic vascular disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15032626     DOI: 10.2174/1568008043340044

Source DB:  PubMed          Journal:  Curr Drug Targets Immune Endocr Metabol Disord        ISSN: 1568-0088


  7 in total

1.  C-reactive protein and lipid parameters in older persons aged 80 years and older.

Authors:  M Cesari; G Onder; V Zamboni; E Capoluongo; A Russo; R Bernabei; M Pahor; F Landi
Journal:  J Nutr Health Aging       Date:  2009-08       Impact factor: 4.075

2.  Serum cholesterol trajectories in the 10 years prior to lymphoma diagnosis.

Authors:  Sharon Hensley Alford; George Divine; Chun Chao; Laurel A Habel; Nalini Janakiraman; Yun Wang; Heather Spencer Feigelson; Delia Scholes; Doug Roblin; Mara M Epstein; Lawrence Engel; Suzanne Havstad; Karen Wells; Marianne Ulcickas Yood; Joan Fortuny; Christine Cole Johnson
Journal:  Cancer Causes Control       Date:  2017-11-30       Impact factor: 2.506

3.  Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids.

Authors:  Raquel F Epand; Vinod K Mishra; Mayakonda N Palgunachari; G M Anantharamaiah; Richard M Epand
Journal:  Biochim Biophys Acta       Date:  2009-06-25

4.  Xanthohumol prevents atherosclerosis by reducing arterial cholesterol content via CETP and apolipoprotein E in CETP-transgenic mice.

Authors:  Hiroshi Hirata; Shuichi Segawa; Moeko Ozaki; Naoyuki Kobayashi; Tatsuro Shigyo; Hitoshi Chiba
Journal:  PLoS One       Date:  2012-11-16       Impact factor: 3.240

5.  The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer.

Authors:  Donovan McGrowder; Cliff Riley; Errol Y St A Morrison; Lorenzo Gordon
Journal:  Cholesterol       Date:  2010-12-23

6.  Effect of anti-ApoA-I antibody-coating of stents on neointima formation in a rabbit balloon-injury model.

Authors:  Aart C Strang; Menno L W Knetsch; Leo H Koole; Robbert J de Winter; Allard C van der Wal; Carlie J M de Vries; Paul P Tak; Radjesh J Bisoendial; Erik S G Stroes; Joris I Rotmans
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

7.  Association of postalimentary lipemia with atherosclerotic manifestations.

Authors:  J Tentor; R T Nakamura; M Gidlund; S Barros-Mazon; L M Harada; V S Zago; J F Oba; E C de Faria
Journal:  Braz J Med Biol Res       Date:  2012-08-09       Impact factor: 2.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.